Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

IGI LABORIGI
Mes dernières consult.
Most popular
Report
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

IGI Laboratories, Inc. : IGI Laboratories Partners with DDN to Provide Pharmaceutical Support Services

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2012 | 10:42pm CET

Buena, NJ - November 13, 2012 - IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic pharmaceutical company, announced today that the Company will partner with DDN, a Dohmen Company, the largest privately-held provider of outsourced business services to the life science industry.    

IGI will launch its first IGI labeled generic products later this year.  DDN will provide product launch support, logistics support and order to cash services.    

Jason Grenfell-Gardner, President and Chief Executive Officer (CEO) of IGI, said, "Our partnership with DDN completes a significant step in our go to market strategy, and we are extremely pleased to have DDN as a partner to help guide us through the logistics regarding the launch of our first IGI labeled products later this year.  As I have mentioned, there were several steps in the execution of our go to market strategy, and now with DDN in place, IGI can focus on aggressively selling and marketing our IGI label products".  

DDN President Mark Wiesman, said, "We look forward to providing support to IGI as they launch their products into the marketplace.  Our goal is to provide broad expertise and scalable infrastructure to life science companies such as IGI, allowing them to focus their attention and capital on rapidly growing their business.  We look forward to partnering with IGI as together we provide outstanding service to their customers."

About IGI Laboratories, Inc.
IGI Laboratories is a developer and manufacturer of topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.

About DDN
DDN, a Dohmen company, provides conflict-free business support services to global emerging, mid-tier and large life science companies. DDN is uniquely aligned with manufacturers to create efficiencies, reduce cost and solve complex business challenges within the healthcare supply system. Visit  HYPERLINK "http://www.ddnnet.com" www.ddnnet.com.  

IGI Laboratories, Inc. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "possible," "one time," "provides an opportunity," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Actual results may differ materially from these expectations due to changes in global political, economic, business, competitive, market and regulatory factors or IGI Laboratories, Inc.'s ability to implement business strategies. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IGI LABORIGI
01/10 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Regulation FD Disclosure
01/10 TELIGENT, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
01/03 Teligent, Inc. to Present at the J.P. Morgan 36th Annual Healthcare Conferenc..
2017 TELIGENT : Announces First FDA Generic Approval of Hydrocortisone Butyrate Lotio..
2017 Teligent, Inc. Announces First FDA Generic Approval of Hydrocortisone Butyrat..
2017 TELIGENT : Announces FDA Approval of Erythromycin Topical Solution USP, 2%
2017 Teligent, Inc. Announces FDA Approval of Erythromycin Topical Solution USP, 2..
2017 TELIGENT INC : Featured Company News - FDA Approved Teligent's Betamethasone Dip..
2017 TELIGENT : Announces FDA Approval of Betamethasone Dipropionate Ointment USP (Au..
2017 Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Ointment ..
More news
Financials ($)
Sales 2017 68,9 M
EBIT 2017 -4,67 M
Net income 2017 -13,8 M
Debt 2017 72,1 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 3,74x
EV / Sales 2018 2,90x
Capitalization 186 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 5,53 $
Spread / Average Target 59%
EPS Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI186
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132